Valuation: Becton, Dickinson and Company

Market Cap 44.07B 38.51B 35.54B 32.76B 61.74B 4,244B 63.11B 425B 167B 2,078B 165B 162B 7,155B P/E 2026 *
39.8x
P/E 2027 * 30.8x
Enterprise Value 60.58B 52.94B 48.85B 45.03B 84.87B 5,834B 86.76B 584B 230B 2,857B 228B 223B 9,836B EV / Sales 2026 *
3.15x
EV / Sales 2027 * 2.94x
Free-Float
74.04%
Yield 2026 *
2.41%
Yield 2027 * 2.45%
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Compliance Officer - 2023-01-31
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.43% - - 44.07B
+0.81%+6.19%-17.24%-6.79% 172B
-0.94%-1.31%-7.55%-4.54% 107B
-0.21%+1.52%+4.64%+60.32% 59.92B
-2.49%-2.51% - - 34.76B
-2.51%+1.72%-9.33%-44.53% 30.09B
-0.80%+1.77%+62.44%-6.17% 25.61B
-0.91%+1.31%-3.73%-18.94% 20.86B
-1.64%+0.87%-2.99%-4.59% 21.55B
+2.74%+1.80%-6.96%+4.13% 20.04B
Average -0.62%+2.50%+2.41%-2.64% 54.66B
Weighted average by Cap. -0.31%+2.95%-5.38%+0.11%

Financials

2026 *2027 *
Net sales 19.21B 16.79B 15.49B 14.28B 26.92B 1,850B 27.52B 185B 72.84B 906B 72.16B 70.57B 3,120B 19.73B 17.24B 15.91B 14.66B 27.63B 1,900B 28.25B 190B 74.78B 930B 74.08B 72.45B 3,203B
Net income 1.12B 983M 907M 836M 1.58B 108B 1.61B 10.84B 4.26B 53.04B 4.22B 4.13B 183B 1.45B 1.27B 1.17B 1.08B 2.03B 140B 2.08B 13.97B 5.49B 68.35B 5.44B 5.32B 235B
Net Debt 16.51B 14.43B 13.32B 12.28B 23.14B 1,590B 23.65B 159B 62.61B 779B 62.02B 60.66B 2,681B 13.96B 12.2B 11.26B 10.37B 19.55B 1,344B 19.99B 135B 52.92B 658B 52.42B 51.27B 2,266B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
159.93USD
Average target price
179.36USD
Spread / Average Target
+12.15%

Quarterly revenue - Rate of surprise